Xeltabine Contraindications

The drug should not be administered in the following patients. Hypersensitivity to Capecitabine (Xeltabine) or to any of the excipients.
History of severe and unexpected reactions to fluoropyrimidine therapy.
During pregnancy and lactation.
In patients with severe renal impairment (creatinine clearance below 30 mL/min).
Treatment with sorivudine or its chemically related analogues, such as brivudine.
In patients with known dihydropyrimidine dehydrogenase (DPD) deficiency (unexpected, severe toxicity (eg, stomatitis, diarrhea, neutropenia and neurotoxicity) associated with fluorouracil can be occurred).
In patients with severe leucopenia, neutropenia, or thrombocytopenia.
In patients with severe hepatic impairment.
In taking a Tegafur, gimeracil, oteracil potassium complex or within seven days after interruption of administration.
As this medicinal product contains anhydrous lactose as an excipient, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.